Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Abstract

Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.

Assessment of clinical epidemiology, treatment patterns, and survival outcomes in epithelial ovarian cancer: a retrospective analysis from a tertiary cancer centre in North India

“…Research pertaining to QoL in women who underwent CRS with the inclusion of bevacizumab or hyperthermic intraperitoneal chemotherapy (HIPEC) demonstrated that the surgical intervention did not have a detrimental effect on their QoL. 19 Boer et al in their study highlighted that a higher QoL was seen in patients who had surgery with the use of the Plasma Jet device at 12 months postoperatively. The Plasma Jet is a thermal plasma energy device.…”

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

“…OC is the main cause of death in women with reproductive malignant tumors. The initial operation, with the goal of R0 resection and platinum‐based combination chemotherapy, is the standard treatment for OC 302,303 . Although the initial pharmacotherapy was encouraging, long‐term use of drugs resulted in drug resistance and was one of the main reasons for the discontinuation of cisplatin during chemotherapy 304–306 .…”

“…The initial operation, with the goal of R0 resection and platinum-based combination chemotherapy, is the standard treatment for OC. 302,303 Although the initial pharmacotherapy was encouraging, long-term use of drugs resulted in drug resistance and was one of the main reasons for the discontinuation of cisplatin during chemotherapy. [304][305][306] Xie et al showed that the application of epigenetic approaches for the diagnosis, clinical treatment, and prognosis of OC is a promising area for future clinical research.…”